Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
about
Effects of exposure to carbon disulphide on low density lipoprotein cholesterol concentration and diastolic blood pressureDietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemiaDietary treatment for familial hypercholesterolaemiaAtherosclerosis--reversal with therapyOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patientsCholesterol lowering and mortality: the importance of considering initial level of riskThe therapeutic role of niacin in dyslipidemia managementWhy are low-density lipoproteins atherogenic?Low-density lipoprotein oxidation and the pathogenesis of atherosclerosisBile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events.Identification of a common low density lipoprotein receptor mutation (R329X) in the south of England: complete linkage disequilibrium with an allele of microsatellite D19S394.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other DyslipidemiasPhysiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementNiacin: another look at an underutilized lipid-lowering medication.Raising HDL cholesterol in women.Hypercholesterolaemia: setting a Dutch national standard.Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL.A comparison of clinical outcome studies among cholesterol-lowering agents.Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective.Niacin for primary and secondary prevention of cardiovascular events.Management of dyslipidemia in women in the post-hormone therapy era.Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2.Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.Does nicotinic acid (niacin) lower blood pressure?Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults.The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletionConsensus statement on management of dyslipidemia in Indian subjects.Lipid lowering by hydroalcoholic extracts of Amaranthus caudatus L. induces regression of rabbits atherosclerotic lesions.Colesevelam HCl: a non-systemic lipid-altering drug.Medical treatment after myocardial infarction. Results of studies using various methods.Primary hypercholesterolemia: genetic causes and treatment of five monogenic disorders.Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
P2860
Q23922518-87723CB9-EE9C-45B5-B734-0B70B323F1E5Q24194060-8726E396-CEC2-4696-92DD-CF9207CFCCFCQ24240324-F0804957-883E-4DDF-94A9-6F5996B03374Q24515243-EA814853-66F0-45FD-B21B-F136E90AA509Q24626884-9E89DCB3-9235-4681-8512-A4782CA4AE70Q28222549-B1245ACF-171D-4193-A03C-F1BD50A3015DQ28244205-FEEAC012-3167-4665-8E40-5F6D7DE28CF3Q28270339-C68CAC1B-3F92-4486-9A50-05DF3A6CBEEEQ28304559-FF1A4040-5D09-4079-ADE1-B16A1494C39AQ33607440-E757548E-2761-4714-A8B3-B1A1C601CE53Q33607486-554E57E5-4987-4AC9-9984-DA24910EA8A3Q33610738-509AD1F1-1276-4003-AB6F-F64FBDCEFC32Q33613217-5E28DBDA-4802-4039-984D-396387C205C6Q33678390-F9E11FA8-16ED-4753-9007-0E9CB70AB20BQ33765072-D778FC46-068F-46B5-BF22-C843641BC86BQ33802196-5F6E5A35-F73A-4E89-8534-4E33C6703A95Q33815841-A7B08450-19FF-4C94-9805-F7206ADBF711Q34037840-B95D3952-9B36-466D-B38F-592FA8290409Q34066977-0BD36E32-EF4E-44E6-9A3E-4C8FDDB95CD5Q34181381-CDB75196-B753-4E94-A4FE-FA485C51E81EQ34255686-A1C65A9C-334A-4DA8-B370-5989CD4A3F90Q34271942-DA789EC3-F670-4656-8B5E-ECA60D332815Q34371039-7BC2760C-4E8A-445E-81FC-D931C8676424Q34377359-59ADAC25-5CB9-4C3E-A0ED-D719348ADDD7Q34495746-F561D5CB-6D77-4B2E-9D78-CA4C42A447E0Q34620714-60401165-2DBB-4A34-9F38-83610D0110DEQ34682221-406A45EF-5485-4253-BFC3-71BBB32E6A20Q34722828-BA790CFD-1D3B-4074-9147-8A2103C65109Q34755080-9C11417C-815D-47E0-993C-038CD93A3E48Q34793071-007504B4-0B29-43EB-BA73-0664E63E4D13Q34894236-F2157886-574B-4780-A38C-CC25813139CAQ34896246-9FD6DB1F-6AD4-4C58-A68E-EDC5FA2A8A36Q34974691-459C8C9B-85A1-4C9B-944E-2E99957C5ED0Q34980772-AB6D6D7A-0811-49FE-BD36-89820F6431D6Q35068227-190BE70A-BA04-4329-98D9-6F74896AC3F3Q35124717-8657A3E9-074D-4487-B0A3-3818673B919CQ35272535-E2C6BF40-F284-467E-95D8-A1A7F39139F1Q35696516-EF4D931B-4133-4301-97D7-86B87BDAC372Q35821517-C8DCAC10-B499-473D-98A4-9F035F726CA4Q35821875-9002C8BF-5AD3-4C2C-B2D1-E1177C455BFA
P2860
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Regression of coronary atheros ...... a with combined drug regimens.
@en
Regression of coronary atheros ...... a with combined drug regimens.
@nl
type
label
Regression of coronary atheros ...... a with combined drug regimens.
@en
Regression of coronary atheros ...... a with combined drug regimens.
@nl
prefLabel
Regression of coronary atheros ...... a with combined drug regimens.
@en
Regression of coronary atheros ...... a with combined drug regimens.
@nl
P2093
P1476
Regression of coronary atheros ...... a with combined drug regimens.
@en
P2093
P304
P356
10.1001/JAMA.1990.03450230043027
P407
P577
1990-12-01T00:00:00Z